The Biosimilar Threat: Which Companies Are at Risk?
Wide-moat Amgen and Roche look the most insulated, while narrow-moat AbbVie looks the most exposed to competition from the generics of the biotech industry.
Wide-moat Amgen and Roche look the most insulated, while narrow-moat AbbVie looks the most exposed to competition from the generics of the biotech industry.
Karen Anderson: Biotech stocks have been among the best-performing stocks since 2011, driven by faster and more successful drug development, the FDA's efforts to expedite approvals, and the fact that larger drug firms need to acquire biotechs to boost their growth as they face generic competition to their own blockbusters. But generics of the biotech industry called biosimilars are just beginning to receive approval in the U.S. Patents on these biologics are beginning to expire, and we now have a regulatory pathway for approval of biosimilars. This does put pressure on the moats of both Big Biotech and Big Pharma firms.
There are really three firms that we think will be hit hardest by biosimilars. They all have more than 40% of their sales coming from products that are among the top 10 targets for biosimilar makers. But we have different views on the valuations of these three firms.
First, wide-moat Amgen (AMGN) looks the most undervalued. We think the firm's very strong cost-cutting efforts and their advancing pipeline more than offset biosimilar pressure. Amgen is positioned to be one of the top three biosimilar players globally as well.
Second, wide-moat Roche (RHHBY) also looks undervalued. The firm has a very strong strategy for replacing sales from their older cancer therapies like Rituxan and Herceptin with more innovative ones.
Finally, we think narrow-moat AbbVie looks overvalued and the most exposed. They have one drug, Humira, which accounts for 60% of the firm's sales. Many firms, including Amgen, are vying to bring biosimilar Humira to market.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.